Sulfadicramide

Summary

Sulfadicramide (CHEMBL2104910) is an approved small molecule (ATC S01AB03); indicated across 1 condition including eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AB03
• Indications: 1 condition
• Chemistry: 254.31 Da · C11H14N2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104910
Name	Sulfadicramide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8281
ATC	S01AB03
Molecular formula	C11H14N2O3S
Molecular weight	254.31
InChIKey	XRVJPLDTMUSSDE-UHFFFAOYSA-N

SMILES: CC(=CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N)C

IUPAC name: N-(4-aminophenyl)sulfonyl-3-methylbut-2-enamide

Also known as: Irgamid, Sulfadicramida, Sulfadicramide, Sulphadicramide, SULFADICRAMIDE

Patent coverage: 373 distinct patent families (1,411 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye infectious disorder	4	MONDO:0043885	EFO:1001888

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).